{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T16:40:23Z","timestamp":1731256823684,"version":"3.28.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,10]]},"DOI":"10.7759\/cureus.73378","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T16:14:40Z","timestamp":1731255280000},"source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapeutic Treatment of an Epidermoid Tumor in a Patient With Zanubrutinib-Treated Mantle Cell Lymphoma: The First Report of Concomitant Treatment"],"prefix":"10.7759","author":[{"given":"Fran\u00e7ois","family":"Fabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis-Philippe","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Delage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain P","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022, 97:638-56. 10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage JO","year":"2022","unstructured":"Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022, 386:2495-506. 10.1056\/NEJMra2202672","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1802424","article-title":"Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma","volume":"19","author":"Makita S","year":"2020","unstructured":"Makita S, Hosoba R, Tobinai K. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opin Drug Saf. 2020, 19:1105-20. 10.1080\/14740338.2020.1802424","journal-title":"Expert Opin Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam CS","year":"2020","unstructured":"Tam CS, Opat S, D'Sa S, et al.. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020, 136:2038-50. 10.1182\/blood.2020006844","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha Y","year":"2023","unstructured":"Sawalha Y, Goyal S, Switchenko JM, et al.. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023, 7:2983-93. 10.1182\/bloodadvances.2022008916","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124195","article-title":"Concurrent use of novel agents and radiation is tolerated in lymphoma patients","volume":"134","author":"Ho CI","year":"2019","unstructured":"Ho CI, Ballard HJ, Arscott WT, et al.. Concurrent use of novel agents and radiation is tolerated in lymphoma patients. Blood. 2019, 134:2905. 10.1182\/blood-2019-124195","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-1375","article-title":"A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy","volume":"11","author":"Zhang R","year":"2022","unstructured":"Zhang R, Sun J. A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy. Transl Cancer Res. 2022, 11:1806-12. 10.21037\/tcr-22-1375","journal-title":"Transl Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1234831","article-title":"Radiotherapy for Non-Hodgkin's lymphoma with cardiac infiltration: a case report","volume":"13","author":"Wang W","year":"2023","unstructured":"Wang W, Zhang Z, Deng X, Gu A, Chen X, Cai Y, Zhao Y. Radiotherapy for Non-Hodgkin's lymphoma with cardiac infiltration: a case report. Front Oncol. 2023, 13:1234831. 10.3389\/fonc.2023.1234831","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255268","article-title":"Bing-Neel syndrome: a rare neurological complication of Waldenstr\u00f6m macroglobulinaemia","volume":"17","author":"Alzghoul H","year":"2024","unstructured":"Alzghoul H, Haider A, Mukhtar F, Khuddus N. Bing-Neel syndrome: a rare neurological complication of Waldenstr\u00f6m macroglobulinaemia. BMJ Case Rep. 2024, 17:10.1136\/bcr-2023-255268","journal-title":"BMJ Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang ML","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al.. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013, 369:507-16. 10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song Y","year":"2022","unstructured":"Song Y, Zhou K, Zou D, et al.. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022, 139:3148-58. 10.1182\/blood.2021014162","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkab050","article-title":"Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies","volume":"5","author":"Tchelebi LT","year":"2021","unstructured":"Tchelebi LT, Batchelder E, Wang M, et al.. Radiotherapy and receptor tyrosine kinase inhibition for solid cancers (ROCKIT): a meta-analysis of 13 studies. JNCI Cancer Spectr. 2021, 5:10.1093\/jncics\/pkab050","journal-title":"JNCI Cancer Spectr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.768692","article-title":"Target-based radiosensitization strategies: concepts and companion animal model outlook","volume":"11","author":"Berry MR","year":"2021","unstructured":"Berry MR, Fan TM. Target-based radiosensitization strategies: concepts and companion animal model outlook. Front Oncol. 2021, 11:768692. 10.3389\/fonc.2021.768692","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo Y","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, et al.. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019, 62:7923-40. 10.1021\/acs.jmedchem.9b00687","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht M","year":"2015","unstructured":"Hecht M, Zimmer L, Loquai C, et al.. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015, 26:1238-44. 10.1093\/annonc\/mdv139","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000044","article-title":"Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib","volume":"24","author":"Liebner DA","year":"2014","unstructured":"Liebner DA, Walston SA, Cavaliere R, et al.. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res. 2014, 24:172-6. 10.1097\/CMR.0000000000000044","journal-title":"Melanoma Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110133","article-title":"The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR\/AKT\/mTOR signaling pathway","volume":"128","author":"Tan B","year":"2020","unstructured":"Tan B, Huang Y, Zhang B, Lin N. The effect of ibrutinib on radiosensitivity in pancreatic cancer cells by targeting EGFR\/AKT\/mTOR signaling pathway. Biomed Pharmacother. 2020, 128:110133. 10.1016\/j.biopha.2020.110133","journal-title":"Biomed Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald C","year":"2021","unstructured":"McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton's tyrosine kinase in the immune system and disease. Immunology. 2021, 164:722-36. 10.1111\/imm.13416","journal-title":"Immunology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2023.03.006","article-title":"Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy","volume":"378","author":"Su C","year":"2023","unstructured":"Su C, Himes JE, Kirsch DG. Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy. Int Rev Cell Mol Biol. 2023, 378:201-32. 10.1016\/bs.ircmb.2023.03.006","journal-title":"Int Rev Cell Mol Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik M","year":"2019","unstructured":"Mhibik M, Wiestner A, Sun C. Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. Int J Mol Sci. 2019, 21:10.3390\/ijms21010068","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/317087-radiotherapeutic-treatment-of-an-epidermoid-tumor-in-a-patient-with-zanubrutinib-treated-mantle-cell-lymphoma-the-first-report-of-concomitant-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T16:14:42Z","timestamp":1731255282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/317087-radiotherapeutic-treatment-of-an-epidermoid-tumor-in-a-patient-with-zanubrutinib-treated-mantle-cell-lymphoma-the-first-report-of-concomitant-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.73378","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,10]]}}}